Core Laboratories N.V. (CLB) Tops Q2 EPS by 1c, Posts Strong Q3 and FY11 Guidance
Core Laboratories N.V. (NYSE: CLB) reported Q2 EPS of $0.90, $0.01 better than the analyst estimate of $0.89. Revenue for the quarter came in at $225.79 million versus the consensus estimate of $219.56 million.
Core Laboratories N.V. sees Q3 2011 EPS of $0.98-$1.00, versus the consensus of $0.98. Core Laboratories N.V. sees Q3 2011 revenue of $230-$245 million, versus the consensus of $234.49 million.
Core Laboratories N.V. sees FY2011 EPS of $3.55-$3.60, versus the consensus of $3.69. Core Laboratories N.V. sees FY2011 revenue of $910-$930 million, versus the consensus of $906.93 million.
Core Laboratories N.V. sees Q3 2011 EPS of $0.98-$1.00, versus the consensus of $0.98. Core Laboratories N.V. sees Q3 2011 revenue of $230-$245 million, versus the consensus of $234.49 million.
Core Laboratories N.V. sees FY2011 EPS of $3.55-$3.60, versus the consensus of $3.69. Core Laboratories N.V. sees FY2011 revenue of $910-$930 million, versus the consensus of $906.93 million.